End-of-day quote
Other stock markets
|
||
- KRW | - |
May. 24 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
May. 10 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
Chart calendar Celltrion, Inc.
Upcoming events on Celltrion, Inc.
Past events on Celltrion, Inc.
2024-05-08 | Q1 2024 Earnings Release |
2024-02-28 | Q4 2023 Earnings Release |
2024-01-09 | JPMorgan Healthcare Conference |
2023-11-06 | Q3 2023 Earnings Release |
2023-09-12 | Roadshow - Day - 2 |
2023-09-11 | Roadshow - Day - 1 |
2023-09-11 03:35 pm | Morgan Stanley Global Healthcare Conference - Fireside Chat |
2023-08-24 03:00 am | Investor Meeting |
2023-08-17 03:30 am | Investor Meeting |
2023-05-07 | Q1 2023 Earnings Release |
2023-03-19 | Q4 2022 Earnings Release |
2022-11-13 | Q3 2022 Earnings Release |
2022-08-15 | Interim 2022 Earnings Release |
2022-05-15 | Q1 2022 Earnings Release |
2022-02-15 | FY 2021 Earnings Release |
2021-11-09 | Q3 2021 Earnings Release |
2021-08-16 | Interim 2021 Earnings Release |
2021-05-11 | Q1 2021 Earnings Release |
2021-02-21 | FY 2020 Earnings Release |
2020-03-29 | FY 2019 Earnings Release |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Billions KRW | Released Forecast Spread | 1 128 1 108 1.81% | 1 849 1 860 -0.58% | 1 891 1 898 -0.36% | 2 284 2 367 -3.53% | 2 176 2 369 -8.11% | 3 485 |
EBITDA Billions KRW | Released Forecast Spread | 537 539 -0.23% | 891 899 -0.89% | 972 947 2.66% | 874 981 -10.95% | 897 1 024 -12.4% | 950 |
EBIT Billions KRW | Released Forecast Spread | 378 401 -5.65% | 712 754 -5.55% | 754 757 -0.48% | 647 751 -13.82% | 651 836 -22.03% | 692 |
Earnings before Tax (EBT) Billions KRW | Released Forecast Spread | 379 397 -4.61% | 651 748 -12.99% | 747 823 -9.29% | 626 799 -21.59% | 671 834 -19.5% | 690 |
Net income Billions KRW | Released Forecast Spread | 298 322 -7.6% | 511 576 -11.17% | 575 603 -4.63% | 533 622 -14.21% | 536 703 -23.81% | 540 |
EPS KRW | Released Forecast Spread | 2 153 2 215 -2.78% | 3 586 4 005 -10.46% | 4 031 4 164 -3.2% | 3 855 4 308 -10.52% | 3 753 4 850 -22.62% | 2 534 |
Announcement Date | 19/02/20 | 22/02/21 | 16/02/22 | 03/03/23 | 29/02/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Billions KRW | Released Forecast Spread | 551 500 10.23% | 596 544 9.66% | 646 585 10.32% | 511 606 -15.67% | 597 600 -0.42% | 524 606 -13.58% | 672 646 4.09% | 383 581 -34.19% | 737 722 2.1% | 793 | 921 | 1 050 | 975 | 1 063 |
EBITDA Billions KRW | Released Forecast Spread | 147 103 42.76% | 200 | 445 | 489 | ||||||||||
EBIT Billions KRW | Released Forecast Spread | 142 189 -24.7% | 199 185 7.29% | 214 202 5.61% | 101 204 -50.77% | 182 194 -6.11% | 183 193 -5.26% | 268 224 19.62% | 18,4 186 -90.07% | 15,4 7,44 107.41% | 94,6 | 232 | 341 | 321 | 374 |
Earnings before Tax (EBT) Billions KRW | Released Forecast Spread | 227 193 17.37% | 217 206 5.24% | 48,5 186 -73.88% | 208 182 14.21% | 190 180 5.68% | 283 224 26.02% | ||||||||
Net income Billions KRW | Released Forecast Spread | 119 129 -8.12% | 183 133 37.8% | 167 159 4.54% | 64,5 160 -59.54% | 167 152 9.92% | 148 156 -5.57% | 222 174 27.63% | 1,05 167 -99.37% | 22,4 7,67 192.67% | 63,0 | 173 | 202 | 296 | 331 |
EPS KRW | Released Forecast Spread | 1 162 791 46.78% | 470 781 -39.79% | 1 155 977 18.26% | 1 034 1 013 2.12% | 1 561 1 097 42.29% | 494 | 954 | 1 330 | ||||||
Announcement Date | 12/05/22 | 05/08/22 | 09/11/22 | 03/03/23 | 08/05/23 | 14/08/23 | 07/11/23 | 29/02/24 | 09/05/24 | - | - | - | - | - |
2024-07-15 01:45 am | ADDLIFE AB: Q2 2024 Earnings Release |
2024-07-21 | MEDPACE HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 | SYNGENE INTERNATIONAL LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-23 | ALKERMES PLC: Q2 2024 Earnings Release (Projected) |
2024-07-23 | IQVIA HOLDINGS INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 | ICON PUBLIC LIMITED COMPANY: Q2 2024 Earnings Release (Projected) |
2024-07-24 | LONZA GROUP AG: Q2 2024 Earnings Release |
2024-07-25 01:00 am | BACHEM HOLDING AG: Q2 2024 Earnings Release |
2024-07-25 | PHARVARIS N.V.: Q2 2024 Earnings Release (Projected) |
2024-07-26 01:00 am | BB BIOTECH AG: Q2 2024 Earnings Release |
Past sector events for Celltrion, Inc.
2024-05-29 04:01 pm | IMMUNOVANT, INC.: Q4 2024 Earnings Release |
2024-05-23 07:00 am | CUREVAC N.V.: Q1 2024 Earnings Release |
2024-05-22 01:00 am | EVOTEC SE: Q1 2024 Earnings Release |
2024-05-21 05:14 pm | ALVOTECH: Q1 2024 Earnings Release |
2024-05-21 07:00 am | EXSCIENTIA PLC: Q1 2024 Earnings Release |
2024-05-17 02:00 am | BIOARCTIC AB: Q1 2024 Earnings Release |
2024-05-15 04:05 pm | CULLINAN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-15 07:00 am | PERSPECTIVE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 | GNI GROUP LTD.: Q1 2024 Earnings Release |
2024-05-14 04:05 pm | KYVERNA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock
- Calendar Celltrion, Inc.